Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801496 | 0.85 | CCR5 (0.38) | CCR5ALDH1A1TSHRHSD11B1KMT2A | |
| SCHEMBL1802660 | 0.85 | L3MBTL1 (0.31) | CCR5ALDH1A1TSHRHSD11B1KMT2A | |
| SCHEMBL1800410 | 0.84 | OPRM1 (0.32) | ALDH1A1HTTHDAC8 | |
| SCHEMBL2943562 | 0.82 | CYP3A4 (0.36) | ALDH1A1KMT2AMEN1HTTHDAC8 | |
| SCHEMBL4032819 | 0.82 | POLB (0.34) | ALDH1A1KMT2AMEN1MAPK1HTT | |
| SCHEMBL1800965 | 0.82 | HDAC8 (0.30) | HDAC8 | |
| SCHEMBL2939906 | 0.82 | TPSAB1 (0.32) | ALDH1A1HTTHDAC8 | |
| SCHEMBL1798561 | 0.81 | CCR5 (0.35) | CCR5ALDH1A1TSHRHSD11B1KMT2A | |
| SCHEMBL4036735 | 0.79 | MAPT (0.43) | ALDH1A1TSHRHTT | |
| SCHEMBL2941205 | 0.78 | MEN1 (0.44) | ITGB3ITGA2BALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | ITGB3 4197/4885ITGA2B 3983/4885CCR5 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.